Affordable Access

deepdyve-link
Publisher Website

Home collection of products of conception: Can chromosomal analysis be obtained?

Authors
  • Siegel, Molly1
  • Amato, Paula2
  • Lee, David2
  • Wu, Diana2
  • Krieg, Sacha2
  • 1 Oregon Health & Science University, Portland, OR, USA. Electronic address: [email protected]
  • 2 Oregon Health & Science University, Portland, OR, USA.
Type
Published Article
Journal
Journal of gynecology obstetrics and human reproduction
Publication Date
May 01, 2021
Volume
50
Issue
5
Pages
101810–101810
Identifiers
DOI: 10.1016/j.jogoh.2020.101810
PMID: 32417456
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The majority of early pregnancy losses are due to chromosomal abnormalities, which can be evaluated by testing the products of conception (POCs). Traditionally, a dilation and curettage (D&C) is recommended to patients to obtain suitable tissue for analysis. This case series sought to determine whether patients with first-trimester pregnancy losses can successfully obtain analysis of POCs if they pass tissue with expectant management or misoprostol, rather than D&C. This is a retrospective cohort study of patients who desired analysis of POCs following an early pregnancy loss. The POCs were collected either at home by patients, or by providers following a D&C, and sent to an outside laboratory for single nucleotide polymorphism (SNP) microarray analysis. Of 50 identified patients, chromosomal analysis was successfully completed on: 22/34 (65%) of patients who passed pregnancy with misoprostol, 14/14 (100%) with D&C, and 1/2 (50%) with expectant management (x2, p = 0.03). Analysis was successful up to 9 days after tissue was collected, and 55 days after diagnosis of loss. In our study, D&C was the superior method to obtain POCs for chromosomal analysis following a miscarriage, but medical and expectant management still had clinically acceptable success rates as well. Although further study is indicated, this small case series suggests that patient counselling regarding miscarriage management and desired chromosomal analysis should continue to include misoprostol and expectant management as inferior but still appropriate alternatives to D&C. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times